Provider Briefing: Chlordiazepoxide Supply in 2026

If your patients have been reporting difficulty filling Chlordiazepoxide prescriptions, this article is for you. Chlordiazepoxide — one of the most established benzodiazepines in clinical practice — has been subject to intermittent supply disruptions that have impacted patient care in clinics, emergency departments, and addiction treatment programs across the country.

This briefing covers the current state of Chlordiazepoxide availability, the forces driving supply constraints, clinical implications for prescribing, and practical tools to help your patients access their medication.

Timeline: How We Got Here

Chlordiazepoxide (brand name Librium) has been FDA-approved since 1960 and remains a mainstay in alcohol withdrawal management. However, several converging trends have made it harder for patients to find:

• 2020-2022: COVID-19 pandemic disrupted pharmaceutical supply chains broadly, including controlled substance manufacturing and distribution.
• 2023: The DEA increased scrutiny of benzodiazepine prescribing and dispensing patterns, leading some pharmacies to reduce inventory of Schedule IV drugs including Chlordiazepoxide.
• 2024-2025: Manufacturer consolidation continued, with fewer generic companies producing Chlordiazepoxide capsules. Spot shortages of the 25 mg strength became more frequent.
• 2026 (current): Chlordiazepoxide is not on the FDA's official drug shortage list, but pharmacy-level availability remains inconsistent, particularly for the 25 mg capsules most commonly used in alcohol withdrawal protocols.

Prescribing Implications

Alcohol Withdrawal Management

Chlordiazepoxide and Diazepam remain the preferred agents for front-loading therapy in severe alcohol withdrawal, as recommended by the American Society of Addiction Medicine (ASAM). When Chlordiazepoxide is unavailable, the following evidence-based substitutions should be considered:

• Diazepam (Valium): The most direct pharmacological equivalent. Both are long-acting benzodiazepines suitable for front-loading protocols. Approximate equivalence: Chlordiazepoxide 25 mg ≈ Diazepam 5 mg.
• Lorazepam (Ativan): Preferred in patients with hepatic impairment due to its glucuronidation metabolism pathway. More predictable pharmacokinetics in patients with liver disease. Approximate equivalence: Chlordiazepoxide 25 mg ≈ Lorazepam 1 mg.
• Oxazepam (Serax): Another option for patients with liver disease. Shorter half-life requires more frequent dosing. Approximate equivalence: Chlordiazepoxide 25 mg ≈ Oxazepam 15 mg.

Note that symptom-triggered dosing using the CIWA-Ar scale should guide therapy regardless of which benzodiazepine is selected. For more detail on how Chlordiazepoxide works at the receptor level, see Chlordiazepoxide mechanism of action explained.

Anxiety Disorders

For patients taking Chlordiazepoxide for generalized or situational anxiety, supply disruptions create an opportunity to reassess treatment plans:

• Consider whether the patient is a candidate for transition to a first-line agent such as an SSRI (e.g., Sertraline), SNRI (e.g., Venlafaxine XR), or Buspirone.
• If continued benzodiazepine therapy is indicated, Diazepam or Lorazepam are the most appropriate substitutes.
• Hydroxyzine (Vistaril) is a non-controlled alternative for mild-to-moderate anxiety, particularly useful in patients with substance use history.

Current Availability Picture

Chlordiazepoxide generic capsules (5 mg, 10 mg, 25 mg) are manufactured by several generic pharmaceutical companies. Supply is generally adequate at the wholesale level but inconsistent at the retail pharmacy level due to:

• DEA production quotas that cap annual manufacturing volumes
• Internal ordering limits at chain pharmacies for Schedule IV substances
• Wholesaler allocation policies that prioritize higher-volume accounts

Independent pharmacies typically have more success obtaining Chlordiazepoxide, as they often have greater flexibility in their wholesale ordering relationships.

Cost and Access in 2026

Generic Chlordiazepoxide remains one of the most affordable benzodiazepines available:

• Retail cash price: Approximately $40 for 30 capsules (25 mg)
• With discount card: $5 to $12 for 30 capsules (25 mg)
• Insurance coverage: Covered by most plans as a Tier 1 or Tier 2 generic; no prior authorization typically required for short-term use

Cost is rarely a barrier for Chlordiazepoxide. The primary access issue is physical availability at the pharmacy. For patients experiencing cost concerns, our provider's guide to helping patients save money on Chlordiazepoxide offers additional resources.

Tools and Resources for Providers

Medfinder for Providers

Medfinder offers a provider-facing tool that helps clinicians and care teams locate pharmacies with medications in stock. You can recommend this resource directly to patients or have your staff use it to identify pharmacies likely to have Chlordiazepoxide available before sending an electronic prescription.

Patient Education Resources

Direct your patients to these articles to help them navigate the supply situation:

• How to find Chlordiazepoxide in stock near you
• Alternatives to Chlordiazepoxide
• Chlordiazepoxide side effects — what to expect
• Chlordiazepoxide drug interactions

Electronic Prescribing Tips

• When e-prescribing Chlordiazepoxide, include the specific strength and quantity clearly.
• Consider sending prescriptions to independent pharmacies when chain pharmacies report stock issues.
• If your EHR allows it, note on the prescription "okay to substitute equivalent benzodiazepine per prescriber" to give the pharmacist flexibility — though this varies by state regulation for controlled substances.

Looking Ahead

The forces driving Chlordiazepoxide supply inconsistency — DEA quotas, manufacturer consolidation, and pharmacy ordering policies — are unlikely to resolve quickly. Providers should:

1. Have a documented protocol for benzodiazepine substitution in alcohol withdrawal.
2. Educate patients proactively about using tools like Medfinder to locate their medication.
3. Consider whether patients on long-term Chlordiazepoxide for anxiety could benefit from transitioning to non-benzodiazepine alternatives.
4. Maintain open communication with pharmacies about availability patterns.

Final Thoughts

Chlordiazepoxide remains a clinically valuable medication, particularly in addiction medicine. While the supply situation is manageable with the right approach, it requires proactive planning from prescribers and care teams. Equip your practice with substitution protocols, direct patients to Medfinder, and use these supply disruptions as an opportunity to optimize treatment plans.

For the patient-facing version of this article, see: Chlordiazepoxide shortage update — what patients need to know.